| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Angiotensin-converting enzyme (ACE); PI3K/Akt signaling pathway; NF-κB signaling pathway. Ganoderic acid N inhibits ACE with an IC₅₀ of 0.941 mM in a cell-free assay. It induces apoptosis in cancer cells by activating caspases and inhibiting the PI3K/Akt signaling pathway. Its anti-inflammatory activity is mediated through inhibition of NF-κB signaling and reduction of pro-inflammatory cytokine production. The compound also has antioxidant and hepatoprotective effects.
|
|---|---|
| ln Vitro |
Ganoderic acid N inhibits ACE in a cell-free assay with an IC₅₀ of 0.941 mM. It induces apoptosis in cancer cells by activating caspases and inhibiting the PI3K/Akt signaling pathway. The compound exhibits anti-inflammatory activity by inhibiting NF-κB signaling and reducing pro-inflammatory cytokine production. It also has antioxidant, hepatoprotective, and anticancer effects, inhibits tumor cell proliferation, and protects against oxidative stress-induced damage.
|
| ln Vivo |
In vivo studies of ganoderic acid N are limited. As a triterpenoid from Ganoderma lucidum with ACE inhibitory, anti-inflammatory, antioxidant, hepatoprotective, and anticancer activities, it has potential for evaluation in animal models of hypertension, inflammation, liver disease, and cancer. Its ability to modulate immune responses and inhibit tumor cell proliferation suggests potential therapeutic applications. Further in vivo studies are needed to characterize its pharmacokinetic and pharmacodynamic properties.
|
| Enzyme Assay |
Non-cell-based assays for ganoderic acid N include ACE inhibition assays using purified ACE and a fluorogenic or chromogenic substrate. The enzyme is incubated with substrate in the presence of various concentrations of the compound, and ACE activity is measured by detecting the cleavage product. The IC₅₀ of 0.941 mM is determined from the dose-response curve. PI3K/Akt kinase activity assays can be performed using recombinant kinases. Standard analytical methods including HPLC, NMR, and mass spectrometry are used for compound characterization.
|
| Cell Assay |
Cell-based assays for ganoderic acid N use various cancer cell lines to assess apoptosis induction and PI3K/Akt signaling inhibition. Cells are treated with the compound at various concentrations, and apoptosis is evaluated by flow cytometry using Annexin V/PI staining and caspase activity assays. PI3K/Akt pathway activation is assessed by Western blot. For anti-inflammatory studies, macrophage cell lines are stimulated with LPS and treated with the compound, and inflammatory cytokine production is measured.
|
| Animal Protocol |
In vivo studies of ganoderic acid N are limited. Based on its biological activities, potential animal models include: hypertension models for ACE inhibition evaluation; tumor xenograft models for anticancer evaluation; liver injury models for hepatoprotective evaluation; and inflammation models for anti-inflammatory evaluation. Standard protocols for these models involve administration of the compound followed by measurement of relevant endpoints.
|
| ADME/Pharmacokinetics |
Ganoderic acid N has a molecular formula of C₃₀H₄₄O₅ and a molecular weight of approximately 484.67 g/mol. It is a triterpenoid isolated from Ganoderma lucidum and G. lingzhi. The compound is soluble in DMSO. It should be stored under recommended conditions. It is intended for research use only.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for ganoderic acid N are limited. As a natural triterpenoid from Ganoderma lucidum, it is generally considered to have low toxicity. The compound exhibits anticancer activity by inducing apoptosis in cancer cells, indicating biological activity at certain concentrations. Standard laboratory safety practices should be followed when handling this compound.
|
| References |
|
| Additional Infomation |
Ganoderma lucidum acid N is a triterpenoid compound.
Ganoderic acid N is a triterpenoid isolated from Ganoderma lucidum and G. lingzhi. It inhibits ACE with an IC₅₀ of 0.941 mM and exhibits anti-inflammatory, antioxidant, hepatoprotective, and anticancer effects. It induces apoptosis in cancer cells by activating caspases and inhibiting the PI3K/Akt signaling pathway. Its anti-inflammatory activity is mediated through NF-κB inhibition. It modulates immune responses and protects against oxidative stress-induced damage. It is for research use only. |
| Molecular Formula |
C30H42O8
|
|---|---|
| Molecular Weight |
530.65
|
| Exact Mass |
530.287
|
| CAS # |
110241-19-5
|
| PubChem CID |
131751706
|
| Appearance |
White to off-white solid
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
725.5±60.0 °C at 760 mmHg
|
| Melting Point |
164 - 167 °C
|
| Flash Point |
406.5±29.4 °C
|
| Vapour Pressure |
0.0±5.3 mmHg at 25°C
|
| Index of Refraction |
1.572
|
| LogP |
1.56
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
38
|
| Complexity |
1160
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(CC(=O)CC(C)(O)C1CC(=O)C2(C)C3=C(C(=O)CC12C)C1(C)CCC(=O)C(C)(C)C1CC3O)C(O)=O |c:15|
|
| InChi Key |
XXHBQOHASACCAP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C30H42O8/c1-15(25(36)37)10-16(31)13-29(6,38)20-12-22(35)30(7)24-17(32)11-19-26(2,3)21(34)8-9-27(19,4)23(24)18(33)14-28(20,30)5/h15,17,19-20,32,38H,8-14H2,1-7H3,(H,36,37)
|
| Chemical Name |
6-hydroxy-6-(7-hydroxy-4,4,10,13,14-pentamethyl-3,11,15-trioxo-1,2,5,6,7,12,16,17-octahydrocyclopenta[a]phenanthren-17-yl)-2-methyl-4-oxoheptanoic acid
|
| Synonyms |
Ganoderic acid N
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 50 mg/mL (94.22 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (2.36 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (2.36 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.25 mg/mL (2.36 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8845 mL | 9.4224 mL | 18.8448 mL | |
| 5 mM | 0.3769 mL | 1.8845 mL | 3.7690 mL | |
| 10 mM | 0.1884 mL | 0.9422 mL | 1.8845 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
